Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Intellia Therapeutics, Inc. - Common Stock (NQ: NTLA )

9.230 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Intellia Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.
The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach. 
Via The Motley Fool
2 Dirt-Cheap Stocks That Could Rocket Higher in a Bull Market
These stocks may take off in a market favoring growth. 
Via The Motley Fool
Why ReNew Energy Global Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of ReNew Energy Global Plc (NASDAQ: RNW) gained during Monday’s session following strong quarterly sales. ReNew Energy Global posted quarterly sales of $345.00 million, topping market estimates... 
Via Benzinga
Analyst Ratings for Intellia Therapeutics
Via Benzinga
2 Brilliant Growth Stocks to Buy and Hold Forever
These two growth stocks could be genuine wealth escalators. 
Via The Motley Fool
Down 45%, Is Intellia a Buy?
Intellia's operating in the high-growth field of gene editing. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Why Intellia Therapeutics Stock Is Surging Tuesday
Intellia Therapeutics Inc (NYSE: NTLA) shares are trading higher Tuesday after the company announced it received European Union orphan d 
Via Benzinga
Cathie Wood Continues On Roku Shares Selling Spree After Company's Q3 Revenue Jump — Ark Sells $21.1M Of Stock
Via Benzinga
3 Biotech Stocks That Are Betting on the Future of Gene Editing
These three companies have gene editing therapies in late-stage clinical trials, making them promising biotech stocks to buy right now. 
Via InvestorPlace
Cathie Wood's ARK Innovation Just Had Its Best Week Ever Thanks To Roku, These Huge Winners
Roku vaulted 50% to become Ark Innovation's top holding. 
Via Investor's Business Daily
1 Supercharged Growth Stock That Could Make You a Millionaire in 10 Years
Biotech may be in a slump, but this innovator holds enormous promise as a potential wealth escalator. 
Via The Motley Fool
Intellia Therapeutics Will Soon Make Biotech History. Is the Stock a Buy?
There's more to being a good investment than doing groundbreaking science. 
Via The Motley Fool
3 Stocks Cathie Wood Is Buying That Should Be on Your List Too
The three companies are positioned to benefit from red-hot trends. 
Via The Motley Fool
Cathie Wood Is Buying These Top Growth Stocks -- and Both Could Make You Richer Over Time
Wood is going all in on gene editing. 
Via The Motley Fool
Cathie Wood's Ark Offloads $6.3M In Tesla Shares Amid EV Maker's Q3 Earnings Disappointment
Via Benzinga
3 Gene Editing Stocks to Generate Super-Charged Gains
As things progress, such techniques may be able to knock out every disease known, creating massive opportunity for gene-editing stocks. 
Via InvestorPlace
Intellia Stumbles As It Aims For A First-Ever In CRISPR Gene Editing
The company can begin a pivotal study of its treatment for cardiomyopathy. 
Via Investor's Business Daily
2 Healthcare Stocks Near 52-Week Highs Still Worth Buying
These two large-cap biopharma companies could have more room to run. 
Via The Motley Fool
2 Growth Stocks That Could Deliver Parabolic Returns in Under 5 Years
These two gene-editing stocks could be diamonds in the rough. 
Via The Motley Fool
Cathie Wood's Ark Invest Sells $9.8M Worth Of Tesla Shares — Second Day Of Selling EV Giant In A Row
Via Benzinga
Cathie Wood's Ark Invest Keeps On Cutting Tesla Holdings, Sells More Than $8M Worth Of EV Maker's Shares
Via Benzinga
This Cathie Wood Stock Is Poised to Double, Says Wall Street
Almost anything is possible in the volatile biotech industry. 
Via The Motley Fool
Intellia Therapeutics Could Rise 167%, Per Wall Street, But Is It a Buy?
Don't bet the farm on the analysts being right -- but they might be. 
Via The Motley Fool
Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Are Gene Therapy Stocks The Market's Next Big Winners?
Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price. 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Better Gene Editing Stock: Intellia Therapeutics vs. Rocket Pharmaceuticals
Rocket could launch its medicines sooner, but Intellia is aiming for larger markets. 
Via The Motley Fool
1 Huge Risk That Gene-Editing Stock Investors Desperately Need to Know
Good medicines aren't always good business. 
Via The Motley Fool
2 Top Trends to Invest $500 In Right Now
Early investors in these trends may reap the rewards over time. 
Via The Motley Fool
Cathie Wood Is Buying These 2 Biotech Stocks Hand Over Fist, and Wall Street Thinks They Could Double
These businesses could be on the verge of takeoff. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.